Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease
Authors:
- Georg Mn BehrensGBGeorg Mn Behrens
- Dirk Meyer-OlsonDMDirk Meyer-Olson
- Matthias StollMSMatthias Stoll
- Reinhold E SchmidtRSReinhold E Schmidt
- 1 April 2003
- journal article
- review article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17, S149-S154
Abstract
Metabolic complications and altered fat distribution associated with HIV infection and antiretroviral therapy may lead to accelerated coronary artery disease (CAD). The high prevalence of multiple cardiovascular risk factors in a significant number of HIV patients is a cause for concern in both patients and physicians. Non-invasive strategies to measure subclinical CAD have been inconclusive. Long-term studies are underway to determine cardiac event rates, intervention strategies and consequences for the clinical management of HIV disease. In the present paper, we summarize the most prevalent risk factors in individuals with HIV infection receiving highly active antiretroviral therapy by focusing on the clinical implications of metabolic abnormalities and HIV-related lipodystrophy on CAD.Keywords
This publication has 33 references indexed in Scilit:
- Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesisAIDS, 2002
- Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13Nature Genetics, 2001
- Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenzAIDS, 2001
- Clinical assessment of HIV-associated lipodystrophy syndrome: bioelectrical impedance analysis, anthropometry and clinical scoresClinical Nutrition, 2001
- Increased PAI-1 and tPA Antigen Levels Are Reduced with Metformin Therapy in HIV-Infected Patients with Fat Redistribution and Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2001
- Lessons from lipodystrophy:LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophyAIDS, 2000
- Lipodystrophy Syndrome in HIV InfectionDrug Safety, 2000
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Regional adiposity and morbidity.Physiological Reviews, 1994